Merck, a leading science and technology company, today announced the opening of its new office in Nigeria by Stefan Oschmann, CEO-elect of Merck, and Karim Bendhaou, President of North & West Africa. It’s the company’s first in the country and part of its strategy to grow its market share in the West African region.
Merck products have already been present in the country for several years and today the company announced that this portfolio was expanded with the launch of the Muse Auto CD4/CD4% System(1), a compact and easy to use HIV/AIDS Diagnostic Kit, which is able to monitor the progression of the HIV/AIDS virus in patients.
“Nigeria is an evident choice for us. With a population that is known for its entrepreneurial spirit and innovative ideas, this is a perfect match with Merck,“ declared Oschmann. “Nigeria, Africa’s largest economy, has one of the fastest growing economies in the world(2) and we believe that through our high quality and innovative Healthcare and Life Science specialty products and services we can contribute to that growth.”
Charles Ajibo, General Manager Nigeria for Biopharma, added “Nigeria is a very important market for us and this will only increase in the coming years. We plan to expand our current portfolio in a steady pace and introduce many more products that are targeted to the unmet medical needs of Nigerian patients and help them improve their daily lives.”
Furthermore, as part of its commitment to improving access to healthcare in developing countries, the company is supporting the World Health Organization (WHO) in the fight against schistosomiasis in Africa.
Since the start of the Merck Praziquantel Donation Program, Merck has donated over 290 million praziquantel tablets. To date, more than 64 million patients have been treated, consisting primarily of school children. Nigeria is currently the largest recipient of the Merck Praziquantel Donation Program.
Until now, Merck has donated nearly 71,000,000 tablets to WHO for Nigeria and another 34 million will follow by the end of this year.